Light chain and light and heavy chain deposition disease (LCDD and LHCDD) are plasma cell dyscrasias in which aggregation and deposition of Ig components leads to organ dysfunction. Although similar in principle to light chain (AL) amyloidosis, there are a number of distinguishing clinical and pathological features. 1 Untreated, the natural history is usually progression to end-stage renal disease with death resulting either from light-chain-mediated organ impairment or complications of concomitant multiple myeloma (MM). Alkylator-based chemotherapy is generally ineffective in controlling disease progression, and high dose therapy with autologous stem cell transplant (ASCT) has been advocated as a means to effect a rapid reduction in pathological light chain production. 2, 3 Data supporting the safety and efficacy of this approach remain limited given the rarity of these conditions.
We reviewed all eight patients with LCDD or LHCDD who underwent ASCT at our institution between August 2006 and November 2009. Baseline characteristics are listed in the Table 1 . The median age of patients at presentation was 48 (40-62 years old). All patients presented with symptomatic renal disease including three with nephrotic syndrome, one with nephritic syndrome and one with acute renal insufficiency requiring dialysis. Renal biopsy demonstrated characteristic findings of light or light and heavy chain deposition in all patients and none had concurrent myeloma cast nephropathy or AL amyloidosis. Two patients met other criteria for symptomatic MM, such as the presence of otherwise unexplained anemia, hypercalcemia or lytic bone disease. No patients had evidence of extrarenal LCDD/LHCDD based on clinical examination, cardiac assessment by echocardiography or radionuclide angiography, pulmonary function testing or routine biochemistry.
Induction therapy varied (Table 1) , but most patients received a dexamethasone-based regimen. Two patients received bortezomib containing regimens. Induction was withheld in one patient in whom there was a concern for reactivation of tuberculosis. All patients underwent stem cell mobilization with filgrastim 10 mcg/kg daily for 3-4 days. Melphalan conditioning was administered at reduced dose (140 mg/m 2 ) in seven cases because of renal dysfunction and 200 mg/m 2 in the eighth. Assessment of response to treatment was adapted from the international consensus criteria for AL amyloidosis. 4 Briefly, hematological complete response (CR) required normalization of k:l free light chain (FLC) ratio, and, when renal function was normal, normalization of FLC levels. BM biopsy was not performed after ASCT to confirm hematological CR. Hematological partial response (PR) required a X50% decrease in the level of involved light chain and was assessable only if the initial FLC level was X100 mg/L. Progressive disease required (i) an increase in the pathological FLC to at least twice the upper limit of normal along with an abnormal FLC ratio in the case of previous CR or (ii) a 50% increase in the pathological FLC to at least X100 mg/L in the case of previous PR. A renal response was defined by a decrease in creatinine by 50% from peak value or a decrease in proteinuria by 50% with stable creatinine: the dual nature of this criterion was chosen to reflect the heterogeneity of renal disease in LCDD and LHCDD. The median time from diagnosis to ASCT was 5 months (3-18 months). There were no significant complications of PBSC mobilization and collection. Median creatinine at the time of ASCT was 183 mmol/L (128-298 mmol/L). No patients had significant cardiac, pulmonary or hepatic comorbidity. Significant toxicities of ASCT are listed in Table 1 . No patients died or required critical care unit admission. One patient with a pre-ASCT creatinine of 298 mmol/L developed acute renal failure and dialysis dependence 2 months post ASCT. Hematological response was CR in one patient and PR in four patients. In three patients, baseline M protein or FLC levels were below the level at which the international consensus criteria allows response assessment. Among these three patients, two had normalization of FLC ratio, whereas the third had a persistent, unquantified, faint band on serial serum protein electrophoresis. Aside from the patient who became dialysis dependent, all patients achieved a renal response including resolution of nephritic and nephrotic syndrome in all affected patients. Modification of the renal response criteria so that response required a 50% improvement in creatinine from baseline rather than peak value resulted in the recategorization of only one patient as a non-responder. After a median follow-up of 26 months (2-40 months), two patients showed evidence of disease progression with increasing FLC levels at 16 and 17 months post ASCT but neither was undergoing treatment at last follow-up.
Our results demonstrate high rates of hematological and renal response in LCDD and LHCDD patients treated with ASCT. Toxicity was acceptable and symptoms of renal dysfunction were, with one exception, eliminated in all patients after completion of treatment. Progression in one patient to ESRD post ASCT is likely explained by a prolonged interval from diagnosis to ASCT (18 months) and poor pre-ASCT renal function (creatinine 298 umol/L). Although the lack of post-treatment BM biopsy limited full assessment of the response depth, hematological response was durable with only two patients showing evidence of progressive disease in follow-up. Toxicity in our study was lower than previously reported in a series of patients with LCDD and LHCDD undergoing ASCT. [5] [6] [7] [8] This difference is likely attributable to the use of CY for stem cell mobilization in the earliest series and to frequent extrarenal LCDD/LHCDD and dialysis-dependent renal disease in others. Still, the results of these studies are generally concordant with our own in that the majority of patients experienced hematological and renal responses that were durable with acceptable toxicity.
A recent report has described successful use of bortezomib in four patients with LCDD. 9 Incorporation of novel agents into the treatment strategy for patients with LCDD and LHCDD will likely be adopted in clinical practice based on their successes in MM although, given the rarity of LCDD/LHCDD, the data to guide decisions on optimal first line therapy will remain limited. This series of eight patients, while small in number, is one of the largest reported to date. Our results support the use of ASCT as a safe and effective means to provide rapid reduction in pathological light chain levels and improvement in end-organ function in selected patients with newly diagnosed LCDD/LHCDD.
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Follow-up duration and time of relapse are relative to the time of ASCT. a FLC analysis was not conducted in this patient with a detectable serum M-protein at diagnosis.
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